Revenue - Disaggregation of Revenue (Detail) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenues		$ 10,012	$ 9,059	$ 30,871	$ 25,395
YUTIQ [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenues	[1]	7,273	3,928	19,305	11,124
DEXYCU [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenues	[2]	2,447	4,659	10,743	13,003
Product [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenues		$ 9,720	$ 8,587	$ 30,048	$ 24,127

[1] Included approximately $4 and $71 of revenue from YUTIQ product sales to Ocumension Therapeutics under a supply agreement for the three and nine months ended September 30, 2022, respectively, and approximately $0 and $19 of revenue from YUTIQ product sales to Ocumension Therapeutics under a supply agreement for the three and nine months ended September 30, 2021, respectively.

[2] Included approximately $16 of revenue from DEXYCU product sales to Ocumension Therapeutics under a supply agreement for the three and nine months ended September 30, 2022, respectively, and approximately $32 of revenue from DEXYCU product sales to Ocumension Therapeutics under a supply agreement for the three and nine months ended September 30, 2021, respectively.